A number of trends (both in science and on the regulatory front)
bode well for the development and availability of drugs to treat
rare diseases. The authors Cinzia Dorigo and Mariah Baltezegar
at Syneos Health say that they believe that a company’s ability to
appreciate the thoughts, values, and preferences of patients and
caregivers will be a primary differentiator for launch success for
products to treat rare diseases.